Trials / Unknown
UnknownNCT03533790
DEP-Ru Regimen as a Salvage Therapy for HLH
DEP-ruxolitinib Regimen as a Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 1 Year – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to investigate the efficacy and safety of ruxolitinib together with liposomal doxorubicin, etoposide and methylprednisolone (DEP-Ru) as a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DEP-Ru | * Drug: ruxolitinib * Drug: doxorubicin * Drug: etoposide * Drug: methylprednisolone |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2018-06-01
- Completion
- 2021-06-01
- First posted
- 2018-05-23
- Last updated
- 2018-05-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03533790. Inclusion in this directory is not an endorsement.